Clinical Trials · NCT05716724

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

Phase
N/A
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
288
Start date
Jan 2023
Locations
20 sites, 3 countries
Primary endpoint
Change in glycated haemoglobin (HbA1c)
View Semaglutide compound reference